BlackRock Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

BlackRock Group’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$145K	Buy	7,007 +609	+10%	+$10.2K	﹤0.01%	2749
2016 Q3	$104K	Buy	6,398 +261	+4%	+$3.79K	﹤0.01%	2812
2016 Q2	$84K	Sell	6,137 -87	-1%	-$1.54K	﹤0.01%	2830
2016 Q1	$108K	Buy	6,224 +2,650	+74%	+$53.9K	﹤0.01%	2743
2015 Q4	$122K	Sell	3,574 -117	-3%	-$4.06K	﹤0.01%	2625
2015 Q3	$110K	Buy	3,691 +982	+36%	+$29.8K	﹤0.01%	2684
2015 Q2	$87K	Buy	+2,709	New	+$69.7K	﹤0.01%	2785
2015 Q1	–	Sell	-626	Closed	-$11K	–	2892
2014 Q4	$11K	Hold	626	–	–	﹤0.01%	2848
2014 Q3	$12K	Hold	626	–	–	﹤0.01%	2795
2014 Q2	$21K	Buy	+626	New	+$19.6K	﹤0.01%	2764

Other funds holding RVNC

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

BlackRock Group's RVNC Position: Q4 2016 in Review

BlackRock Group increased its Revance Therapeutics, Inc. (RVNC) stake by 9.5% in Q4 2016, buying an estimated $10.2K and bringing the position to 7,007 shares worth $145K. The position accounts for ﹤0.01% of the portfolio, ranked #2749.

BlackRock Group first reported a position in RVNC in Q2 2014 and has held it in 10 quarters since. 81 funds tracked by Wall St. Rank hold RVNC as of Q4 2016.

BlackRock Group held 7,007 shares of Revance Therapeutics, Inc. worth $145K as of Q4 2016.
BlackRock Group bought 609 Revance Therapeutics, Inc. shares in Q4 2016, an estimated $10.2K.
Revance Therapeutics, Inc. made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2749 holding.
BlackRock Group first reported a position in Revance Therapeutics, Inc. in Q2 2014 and has held it in 10 quarters since.
81 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.